<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="bootstrap-5.1.3/dist/css/bootstrap.css">
    <title>ya</title>
    <style>
        a{
            text-decoration: none;
        }
     
    </style>
</head>
<body>
    <div class="container">
        <div class="row align-items-start">
          <div class="col-md-8 py-5">
            <div class="input-group mb-3">
                <input type="text" class="form-control" placeholder="Search News"  aria-describedby="button-addon2">
                <button type="button" class="btn btn-primary">Search</button>
            </div>
            <br>
            
            <main id="container" class="container">

	
	
                <p>The following drugs have recently been approved by the FDA. Includes newly approved drugs and new indications for drugs already approved.</p>
                <p>See also: <a href="/generic-approvals.html">Generic approvals</a>, <a href="/fda-approval-process.html">Approval process</a>, <a href="/new-indications.html">New indications &amp; dosage forms</a></p>
            
                <div class="ddc-media-list ddc-mgt-4">
                                <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/pro/alymsys.html">Alymsys</a> (bevacizumab-maly)  Injection</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> <a href="/manufacturer/amneal-pharmaceuticals-llc-19.html">Amneal Pharmaceuticals LLC</a><br>
            
                                                                                                    <b>Date of Approval:</b> April 13, 2022<br>
                                                                                                    <b>Treatment for:</b> Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer<br>
                                                                </p>
                                                    <p>Alymsys (bevacizumab-maly) is a vascular endothelial growth factor inhibitor biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including metastatic colorectal cancer; non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-alymsys-bevacizumab-maly-biosimilar-avastin-5819.html">FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin</a> - April 13, 2022</li>
                                                                                                    <li><a href="/history/alymsys.html">Alymsys FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div id="display-ad-injection-1" class="display-ad display-ad-injection display-ad-lazy display-ad-prebid display-ad-728 display-ad-728x90"></div><div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/vijoice.html">Vijoice</a> (alpelisib)  Tablets</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> <a href="/manufacturer/novartis-pharmaceuticals-corporation-100.html">Novartis Pharmaceuticals Corporation</a><br>
            
                                                                                                    <b>Date of Approval:</b> April 5, 2022<br>
                                                                                                    <b>Treatment for:</b> PIK3CA-Related Overgrowth Spectrum<br>
                                                                </p>
                                                    <p>Vijoice (alpelisib) is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-vijoice-alpelisib-pik3ca-related-overgrowth-spectrum-pros-5817.html">FDA Approves Vijoice (alpelisib) for the Treatment of PIK3CA-Related Overgrowth Spectrum (PROS)</a> - April 6, 2022</li>
                                                                                                    <li><a href="/history/vijoice.html">Vijoice FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title">Igalmi (dexmedetomidine)  Sublingual Film</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> BioXcel Therapeutics, Inc.<br>
            
                                                                                                    <b>Date of Approval:</b> April 5, 2022<br>
                                                                                                    <b>Treatment for:</b> Agitation<br>
                                                                </p>
                                                    <p>Igalmi (dexmedetomidine) is a sublingual film formulation of the approved alpha2-adrenergic receptor agonist dexmedetomidine indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-igalmi-dexmedetomidine-sublingual-film-acute-agitation-associated-schizophrenia-5818.html">FDA Approves Igalmi (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults</a> - April 6, 2022</li>
                                                                                                    <li><a href="/history/igalmi.html">Igalmi FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/tlando.html">Tlando</a> (testosterone)  Capsules</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> Antares Pharma, Inc.<br>
            
                                                                                                    <b>Date of Approval:</b> March 28, 2022<br>
                                                                                                    <b>Treatment for:</b> Hypogonadism, Male<br>
                                                                </p>
                                                    <p>Tlando (testosterone) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-tlando-testosterone-undecanoate-male-hypogonadism-5812.html">FDA Approves Tlando (testosterone undecanoate) for Male Hypogonadism</a> - March 29, 2022</li>
                                                                                                    <li><a href="/history/tlando.html">Tlando FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/pluvicto.html">Pluvicto</a> (lutetium lu 177 vipivotide tetraxetan)  Injection</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> <a href="/manufacturer/novartis-pharmaceuticals-corporation-100.html">Novartis Pharmaceuticals Corporation</a><br>
            
                                                                                                    <b>Date of Approval:</b> March 23, 2022<br>
                                                                                                    <b>Treatment for:</b> Prostate Cancer<br>
                                                                </p>
                                                    <p>Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent indicated for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-pluvicto-lutetium-lu-177-vipivotide-tetraxetan-targeted-radioligand-therapy-5807.html">FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Targeted Radioligand Therapy for Treatment of Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer</a> - March 23, 2022</li>
                                                                                                    <li><a href="/history/pluvicto.html">Pluvicto FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div id="display-ad-injection-2" class="display-ad display-ad-injection display-ad-lazy display-ad-prebid display-ad-728 display-ad-728x90"></div><div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/pro/locametz.html">Locametz</a> (gallium Ga 68 gozetotide)  Injection</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> <a href="/manufacturer/novartis-pharmaceuticals-corporation-100.html">Novartis Pharmaceuticals Corporation</a><br>
            
                                                                                                    <b>Date of Approval:</b> March 23, 2022<br>
                                                                                                    <b>Treatment for:</b> Positron Emission Tomography Imaging<br>
                                                                </p>
                                                    <p>Locametz (kit for the preparation of gallium Ga 68 gozetotide injection) after radiolabeling with gallium-68, is a radioactive diagnostic agent used for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-locametz-kit-preparation-gallium-ga-68-gozetotide-psma-pet-imaging-patients-prostate-5808.html">FDA Approves Locametz (kit for the preparation of gallium Ga 68 gozetotide injection) for PSMA PET Imaging in Patients with Prostate Cancer</a> - March 23, 2022</li>
                                                                                                    <li><a href="/history/locametz.html">Locametz FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/xelstrym.html">Xelstrym</a> (dextroamphetamine)  Transdermal System</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> Noven Pharmaceuticals, Inc.<br>
            
                                                                                                    <b>Date of Approval:</b> March 22, 2022<br>
                                                                                                    <b>Treatment for:</b> ADHD<br>
                                                                </p>
                                                    <p>Xelstrym (dextroamphetamine) transdermal system is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and children 6 years and older.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-xelstrym-dextroamphetamine-transdermal-attention-deficit-hyperactivity-disorder-adhd-5805.html">FDA Approves Xelstrym (dextroamphetamine) Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)</a> - March 23, 2022</li>
                                                                                                    <li><a href="/history/xelstrym.html">Xelstrym FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/hyftor.html">Hyftor</a> (sirolimus)  Topical Gel</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> Nobelpharma America, LLC<br>
            
                                                                                                    <b>Date of Approval:</b> March 22, 2022<br>
                                                                                                    <b>Treatment for:</b> Facial Angiofibroma Associated with Tuberous Sclerosis<br>
                                                                </p>
                                                    <p>Hyftor (sirolimus topical gel) is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-hyftor-sirolimus-topical-gel-facial-angiofibroma-associated-tuberous-sclerosis-5815.html">FDA Approves Hyftor (sirolimus topical gel) for Facial Angiofibroma Associated with Tuberous Sclerosis</a> - April 4, 2022</li>
                                                                                                    <li><a href="/history/hyftor.html">Hyftor FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/ztalmy.html">Ztalmy</a> (ganaxolone)  Oral Suspension</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> Marinus Pharmaceuticals, Inc.<br>
            
                                                                                                    <b>Date of Approval:</b> March 18, 2022<br>
                                                                                                    <b>Treatment for:</b> CDKL5 Deficiency Disorder<br>
                                                                </p>
                                                    <p>Ztalmy (ganaxolone) is neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD).</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-ztalmy-ganaxolone-seizures-associated-cdkl5-deficiency-disorder-5803.html">FDA Approves Ztalmy (ganaxolone) for Seizures Associated with CDKL5 Deficiency Disorder</a> - March 18, 2022</li>
                                                                                                    <li><a href="/history/ztalmy.html">Ztalmy FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/opdualag.html">Opdualag</a> (nivolumab and relatlimab-rmbw)  Injection</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> <a href="/manufacturer/bristol-myers-squibb-company-33.html">Bristol-Myers Squibb Company</a><br>
            
                                                                                                    <b>Date of Approval:</b> March 18, 2022<br>
                                                                                                    <b>Treatment for:</b> Melanoma<br>
                                                                </p>
                                                    <p>Opdualag (nivolumab and relatlimab-rmbw) is programmed death receptor-1 (PD-1) blocking antibody and lymphocyte activation gene-3 (LAG-3) blocking antibody combination indicated for the treatment of unresectable or metastatic melanoma.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-opdualag-nivolumab-relatlimab-rmbw-patients-unresectable-metastatic-melanoma-5804.html">FDA Approves Opdualag (nivolumab and relatlimab-rmbw) for the Treatment of Patients with Unresectable or Metastatic Melanoma</a> - March 18, 2022</li>
                                                                                                    <li><a href="/history/opdualag.html">Opdualag FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/history/nasonex-24hr-allergy.html">Nasonex 24HR Allergy</a> (mometasone furoate monohydrate)  Nasal Spray</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> <a href="/manufacturer/perrigo-company-112.html">Perrigo Company</a><br>
            
                                                                                                    <b>Date of Approval:</b> March 17, 2022<br>
                                                                                                    <b>Treatment for:</b> Allergic Rhinitis<br>
                                                                </p>
                                                    <p>Nasonex 24HR Allergy (mometasone furoate monohydrate) is a corticosteroid nasal spray available over-the-counter for the temporary relief of the symptoms of hayfever or other upper respiratory allergies.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-nasonex-24hr-allergy-mometasone-furoate-nasal-otc-5802.html">FDA Approves Nasonex 24HR Allergy (mometasone furoate) Nasal Spray for OTC Use</a> - March 17, 2022</li>
                                                                                                    <li><a href="/history/nasonex-24hr-allergy.html">Nasonex 24HR Allergy FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div id="display-ad-injection-3" class="display-ad display-ad-injection display-ad-lazy display-ad-prebid display-ad-728 display-ad-728x90"></div><div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/adlarity.html">Adlarity</a> (donepezil)  Transdermal System</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> Corium, Inc.<br>
            
                                                                                                    <b>Date of Approval:</b> March 11, 2022<br>
                                                                                                    <b>Treatment for:</b> Alzheimer's Disease<br>
                                                                </p>
                                                    <p>Adlarity (donepezil transdermal system) is a once-weekly transdermal formulation of the approved acetylcholinesterase inhibitor donepezil indicated for the treatment of Alzheimer’s type dementia.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-adlarity-donepezil-transdermal-patients-alzheimer-s-5798.html">FDA Approves Adlarity (donepezil transdermal system) for Treatment of Patients with Alzheimer’s Disease</a> - March 14, 2022</li>
                                                                                                    <li><a href="/history/adlarity.html">Adlarity FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/vonjo.html">Vonjo</a> (pacritinib)  Capsules</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> CTI BioPharma Corp.<br>
            
                                                                                                    <b>Date of Approval:</b> February 28, 2022<br>
                                                                                                    <b>Treatment for:</b> Myelofibrosis<br>
                                                                </p>
                                                    <p>Vonjo (pacritinib) is a JAK2/FLT3 multikinase inhibitor for the treatment of myelofibrosis patients with severe thrombocytopenia.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-vonjo-pacritinib-adult-patients-myelofibrosis-thrombocytopenia-5790.html">FDA Approves Vonjo (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia</a> - February 28, 2022</li>
                                                                                                    <li><a href="/history/vonjo.html">Vonjo FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/carvykti.html">Carvykti</a> (ciltacabtagene autoleucel)  Suspension for Intravenous Infusion</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> <a href="/manufacturer/janssen-pharmaceuticals-inc-74.html">Janssen Pharmaceuticals, Inc.</a><br>
            
                                                                                                    <b>Date of Approval:</b> February 28, 2022<br>
                                                                                                    <b>Treatment for:</b> Multiple Myeloma<br>
                                                                </p>
                                                    <p>Carvykti (ciltacabtagene autoleucel) is a BCMA-directed CAR-T immunotherapy for the treatment of patients with relapsed or refractory multiple myeloma.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-carvykti-ciltacabtagene-autoleucel-bcma-directed-car-t-immunotherapy-patients-relapsed-5795.html">FDA Approves Carvykti (ciltacabtagene autoleucel) BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma</a> - February 28, 2022</li>
                                                                                                    <li><a href="/history/carvykti.html">Carvykti FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/pro/releuko.html">Releuko</a> (filgrastim-ayow)  Injection</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> <a href="/manufacturer/amneal-pharmaceuticals-llc-19.html">Amneal Pharmaceuticals LLC</a><br>
            
                                                                                                    <b>Date of Approval:</b> February 25, 2022<br>
                                                                                                    <b>Treatment for:</b> Neutropenia Associated with Chemotherapy, Neutropenia<br>
                                                                </p>
                                                    <p>Releuko (filgrastim-ayow) is a recombinant human granulocyte colony-stimulating factor biosimilar to Neupogen indicated for the treatment of neutropenia associated with chemotherapy and related conditions.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-releuko-filgrastim-ayow-biosimilar-neupogen-5793.html">FDA Approves Releuko (filgrastim-ayow), a  Biosimilar to Neupogen</a> - March 2, 2022</li>
                                                                                                    <li><a href="/history/releuko.html">Releuko FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/history/norliqva.html">Norliqva</a> (amlodipine besylate)  Oral Solution</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> CMP Pharma, Inc.<br>
            
                                                                                                    <b>Date of Approval:</b> February 24, 2022<br>
                                                                                                    <b>Treatment for:</b> High Blood Pressure, Coronary Artery Disease, Angina<br>
                                                                </p>
                                                    <p>Norliqva (amlodipine besylate) is an oral solution formulation of the approved calcium channel blocker amlodipine for the treatment of hypertension and angina in patients with coronary artery disease.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-norliqva-amlodipine-oral-solution-hypertension-coronary-artery-5792.html">FDA Approves Norliqva (amlodipine) Oral Solution for Hypertension and Coronary Artery Disease</a> - February 28, 2022</li>
                                                                                                    <li><a href="/history/norliqva.html">Norliqva FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/pro/nephroscan.html">NephroScan</a> (technetium Tc 99m succimer)  Injection Kit</h2>
                                                        <p class="drug-subtitle">
                                                                                                    <b>Date of Approval:</b> February 22, 2022<br>
                                                                                                    <b>Treatment for:</b> Diagnosis and Investigation<br>
                                                                </p>
                                                    <p>NephroScan (kit for the preparation of technetium Tc 99m succimer injection) is a radioactive diagnostic agent indicated for use as an aid in the scintigraphic evaluation of renal parenchymal disorders.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-nephroscan-kit-preparation-technetium-tc-99m-succimer-radiodiagnostic-imaging-5789.html">FDA Approves NephroScan (Kit for the Preparation of Technetium Tc 99m Succimer Injection) for Radiodiagnostic Imaging</a> - February 21, 2022</li>
                                                                                                    <li><a href="/history/nephroscan.html">NephroScan FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div id="display-ad-injection-4" class="display-ad display-ad-injection display-ad-lazy display-ad-prebid display-ad-300 display-ad-300x250"></div><div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/pyrukynd.html">Pyrukynd</a> (mitapivat)  Tablets</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> <a href="/manufacturer/agios-pharmaceuticals-inc-627.html">Agios Pharmaceuticals, Inc.</a><br>
            
                                                                                                    <b>Date of Approval:</b> February 17, 2022<br>
                                                                                                    <b>Treatment for:</b> Pyruvate Kinase Deficiency<br>
                                                                </p>
                                                    <p>Pyrukynd (mitapivat) is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-pyrukynd-mitapivat-first-modifying-therapy-hemolytic-anemia-adults-pyruvate-kinase-5787.html">FDA Approves Pyrukynd (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency</a> - February 17, 2022</li>
                                                                                                    <li><a href="/history/pyrukynd.html">Pyrukynd FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/enjaymo.html">Enjaymo</a> (sutimlimab-jome)  Injection</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> <a href="/manufacturer/sanofi-126.html">Sanofi</a><br>
            
                                                                                                    <b>Date of Approval:</b> February 4, 2022<br>
                                                                                                    <b>Treatment for:</b> Cold Agglutinin Disease<br>
                                                                </p>
                                                    <p>Enjaymo (sutimlimab-jome) is a classical complement inhibitor indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD).</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-enjaymo-sutimlimab-jome-patients-cold-agglutinin-5783.html">FDA Approves Enjaymo (sutimlimab-jome) for Use in Patients with Cold Agglutinin Disease</a> - February 5, 2022</li>
                                                                                                    <li><a href="/history/enjaymo.html">Enjaymo FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                            <div class="ddc-media">
                            <div class="ddc-media-content">
                                <h2 class="ddc-media-title"><a href="/pro/fleqsuvy.html">Fleqsuvy</a> (baclofen)  Oral Suspension</h2>
                                                        <p class="drug-subtitle">
                                                                        <b>Company:</b> <a href="/manufacturer/azurity-pharmaceuticals-580.html">Azurity Pharmaceuticals</a><br>
            
                                                                                                    <b>Date of Approval:</b> February 4, 2022<br>
                                                                                                    <b>Treatment for:</b> Spasticity<br>
                                                                </p>
                                                    <p>Fleqsuvy (baclofen) is an oral suspension formulation of baclofen for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.</p>
                                                        <ul class="previous_application">
                                                                        <li><a href="/newdrugs/fda-approves-fleqsuvy-baclofen-oral-suspension-spasticity-5784.html">FDA Approves Fleqsuvy (baclofen oral suspension) for the Treatment of Spasticity</a> - February 7, 2022</li>
                                                                                                    <li><a href="/history/fleqsuvy.html">Fleqsuvy FDA Approval History</a></li>
                                                                </ul>
                                                </div>
                        </div>
            
                                
                                <a class="ddc-link-forward noprint" href="/newdrugs-archive/february-2022.html">View older articles</a>
                        </div>
            </div>
            
            <div class="contentBox contentBoxNewsArchive">
                <h2>FDA Drug Approvals Archive</h2>
                <form method="get" action="/search.php" class="ddc-mgb-2">
                        <input type="hidden" name="sources[]" value="newdrugapprovals">
                
                        <div class="container">
                            <div class="row align-items-start">
                              <div class="col-md-8 py-5">
                                <div class="input-group mb-3">
                                    <input type="text" class="form-control" placeholder="Search News"  aria-describedby="button-addon2">
                                    <button type="button" class="btn btn-primary">Search</button>
                                </div>
                </div>
            </form>
                <dl class="ddc-mgt-2 ddc-text-size-small">
                        <dt>2022</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2022.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2022.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2022.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2022.html">April</a>
                                </dd>
                        <dt>2021</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2021.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2021.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2021.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2021.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2021.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2021.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2021.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2021.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2021.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2021.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2021.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2021.html">December</a>
                                </dd>
                        <dt>2020</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2020.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2020.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2020.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2020.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2020.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2020.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2020.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2020.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2020.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2020.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2020.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2020.html">December</a>
                                </dd>
                        <dt>2019</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2019.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2019.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2019.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2019.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2019.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2019.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2019.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2019.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2019.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2019.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2019.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2019.html">December</a>
                                </dd>
                        <dt>2018</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2018.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2018.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2018.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2018.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2018.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2018.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2018.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2018.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2018.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2018.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2018.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2018.html">December</a>
                                </dd>
                        <dt>2017</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2017.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2017.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2017.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2017.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2017.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2017.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2017.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2017.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2017.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2017.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2017.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2017.html">December</a>
                                </dd>
                        <dt>2016</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2016.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2016.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2016.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2016.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2016.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2016.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2016.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2016.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2016.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2016.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2016.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2016.html">December</a>
                                </dd>
                        <dt>2015</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2015.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2015.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2015.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2015.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2015.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2015.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2015.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2015.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2015.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2015.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2015.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2015.html">December</a>
                                </dd>
                        <dt>2014</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2014.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2014.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2014.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2014.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2014.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2014.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2014.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2014.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2014.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2014.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2014.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2014.html">December</a>
                                </dd>
                        <dt>2013</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2013.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2013.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2013.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2013.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2013.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2013.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2013.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2013.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2013.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2013.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2013.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2013.html">December</a>
                                </dd>
                        <dt>2012</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2012.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2012.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2012.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2012.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2012.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2012.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2012.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2012.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2012.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2012.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2012.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2012.html">December</a>
                                </dd>
                        <dt>2011</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2011.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2011.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2011.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2011.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2011.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2011.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2011.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2011.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2011.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2011.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2011.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2011.html">December</a>
                                </dd>
                        <dt>2010</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2010.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2010.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2010.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2010.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2010.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2010.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2010.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2010.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2010.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2010.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2010.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2010.html">December</a>
                                </dd>
                        <dt>2009</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2009.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2009.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2009.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2009.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2009.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2009.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2009.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2009.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2009.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2009.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2009.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2009.html">December</a>
                                </dd>
                        <dt>2008</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2008.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2008.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2008.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2008.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2008.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2008.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2008.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2008.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2008.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2008.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2008.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2008.html">December</a>
                                </dd>
                        <dt>2007</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2007.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2007.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2007.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2007.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2007.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2007.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2007.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2007.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2007.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2007.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2007.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2007.html">December</a>
                                </dd>
                        <dt>2006</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2006.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2006.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2006.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2006.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2006.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2006.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2006.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2006.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2006.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2006.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2006.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2006.html">December</a>
                                </dd>
                        <dt>2005</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2005.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2005.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2005.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2005.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2005.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2005.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2005.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2005.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2005.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2005.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2005.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2005.html">December</a>
                                </dd>
                        <dt>2004</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2004.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2004.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2004.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2004.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2004.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2004.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2004.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2004.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2004.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2004.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2004.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2004.html">December</a>
                                </dd>
                        <dt>2003</dt>
                    <dd>
                                        <a href="/newdrugs-archive/january-2003.html">January</a>, 
                                        <a href="/newdrugs-archive/february-2003.html">February</a>, 
                                        <a href="/newdrugs-archive/march-2003.html">March</a>, 
                                        <a href="/newdrugs-archive/april-2003.html">April</a>, 
                                        <a href="/newdrugs-archive/may-2003.html">May</a>, 
                                        <a href="/newdrugs-archive/june-2003.html">June</a>, 
                                        <a href="/newdrugs-archive/july-2003.html">July</a>, 
                                        <a href="/newdrugs-archive/august-2003.html">August</a>, 
                                        <a href="/newdrugs-archive/september-2003.html">September</a>, 
                                        <a href="/newdrugs-archive/october-2003.html">October</a>, 
                                        <a href="/newdrugs-archive/november-2003.html">November</a>, 
                                        <a href="/newdrugs-archive/december-2003.html">December</a>
                                </dd>
                        <dt>2002</dt>
                    <dd>
                                        <a href="/newdrugs-archive/april-2002.html">April</a>, 
                                        <a href="/newdrugs-archive/august-2002.html">August</a>, 
                                        <a href="/newdrugs-archive/october-2002.html">October</a>, 
                                        <a href="/newdrugs-archive/december-2002.html">December</a>
                                </dd>
                </dl>
            </div>
            
            <div class="alert alert-secondary" role="alert">
                <h4>Subscribe to our newsletters</h4>
              <div class="form-check">
                <input class="form-check-input" type="checkbox" value="" id="flexCheckDefault">
                <label class="form-check-label" for="flexCheckDefault">
                    FDA Safety Alerts
                </label>
              </div>
              <div class="form-check">
                <input class="form-check-input" type="checkbox" value="" id="flexCheckDefault">
                <label class="form-check-label" for="flexCheckDefault">
                    Daily MedNews
                </label>
              </div>
              <div class="form-check">
                <input class="form-check-input" type="checkbox" value="" id="flexCheckDefault">
                <label class="form-check-label" for="flexCheckDefault">
                    Monthly Newsletter
                </label>
              </div>
              <div class="form-check">
                <input class="form-check-input" type="checkbox" value="" id="flexCheckDefault">
                <label class="form-check-label" for="flexCheckDefault">
                    I accept the Terms and Privacy Policy
                </label>
              </div>
              <div class="form">
                <div class="input-group mb-3">
                    <input type="text" class="form-control" placeholder="Email Address" aria-label="Email address" aria-describedby="button-addon2">
                    <button class="btn btn-primary" type="button" id="button-addon2">Subscribe</button>
                  </div>

              </div>
            </div>
        </div>
    </div>
</body>
</html>
